Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease [M15-737]
Phase 3
Recruiting
- Conditions
- Parkinson's Disease
- Registration Number
- JPRN-jRCT2080225358
- Lead Sponsor
- AbbVie G.K
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Participants who have Parkinson's Disease and who have successfully completed the parent study M15-741.
- Participants willing and able to comply with procedures required in the protocol.
Exclusion Criteria
- Participants, if judged by the investigator to be unsuitable candidates to continue to receive ABBV-951 for any reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method